Newman Ferrara LLP Announces Corporate Governance Investigations of Zentalis Pharmaceuticals, Inc. (ZNTL)
NEW YORK--(BUSINESS WIRE)--Jan 10, 2023--
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (“Zentalis” or the “Company”). The investigations concern whether certain of the Zentalis’ officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company’s business practices.
Current stockholders of Zentalis that seek more information on this matter are invited to contact Newman Ferrara attorneys Jeffrey Norton ( firstname.lastname@example.org ) or Benjamin Baker ( email@example.com ) to discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at www.nfllp.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230110005919/en/
CONTACT: Newman Ferrara LLP
Jeffrey M. Norton
1250 Broadway, 27thFl.
New York, NY 10001
KEYWORD: NEW YORK UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL
SOURCE: Newman Ferrara LLP
Copyright Business Wire 2023.
PUB: 01/10/2023 01:14 PM/DISC: 01/10/2023 01:14 PM